Arimidex

PMID: 41317675

Is anastrozole really better than tamoxifen for low-risk breast cancer?

Den Jennifer, Baughn Caroline, Klimberg V Suzanne

American journal of surgery · 2026

PMID: 33579961

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.

Buus Richard, Szijgyarto Zsolt, Schuster Eugene F et al.

NPJ breast cancer · 2025

PMID: 31965545

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.

Kim Yoo Jung, Cohen Philip R

Dermatology and therapy · 2024

PMID: 37533837

Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.

Dejthevaporn Thitiya, Patanayindee Panchanin

Breast cancer : basic and clinical research · 2023

PMID: 36877283

Elacestrant (Orserdu) for advanced or metastatic breast cancer.

The Medical letter on drugs and therapeutics · 2023

PMID: 38095411

Oxygen-ozone autohemotherapy in breast cancer patients suffering from fatigue and musculoskeletal pain upon aromatase inhibitors treatment: a case-series study.

Tirelli U, Valdenassi L, Franzini M et al.

European review for medical and pharmacological sciences · 2023

PMID: 35172273

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.

Pece Salvatore, Sestak Ivana, Montani Francesca et al.

European journal of cancer (Oxford, England : 1990) · 2022

PMID: 34726185

Poorly Differentiated Scrotal Carcinoma With Apocrine Immunophenotype.

Kamanda Sonia, Epstein Jonathan I, Osunkoya Adeboye O et al.

The American Journal of dermatopathology · 2022

PMID: 34356536

Role of Persistent Organic Pollutants in Breast Cancer Progression and Identification of Estrogen Receptor Alpha Inhibitors Using In-Silico Mining and Drug-Drug Interaction Network Approaches.

Zainab Bibi, Ayaz Zainab, Rashid Umer et al.

Biology · 2021

PMID: 31753693

Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.

Xiao Hong, Jiang Xinyi, Chen Cheng et al.

Research in social & administrative pharmacy : RSAP · 2021

PMID: 29659187

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Male Volunteers: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study.

Chen Jiangying, Zhuang Jialang, Wu Jingguo et al.

Clinical pharmacology in drug development · 2020

PMID: 31875785

Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion: a case report.

Moon Jung-Eun, Ko Cheol Woo, Yang Jung Dug et al.

BMC pediatrics · 2020

PMID: 31264581

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.

Harnan Sue, Tappenden Paul, Cooper Katy et al.

Health technology assessment (Winchester, England) · 2020

PMID: 29676944

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett Mitch, Sestak Ivana, Regan Meredith M et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019

PMID: 29045530

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.

Fribbens C, Garcia Murillas I, Beaney M et al.

Annals of oncology : official journal of the European Society for Medical Oncology · 2019

PMID: 28252242

Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.

Jinih Marcel, Relihan Norma, Corrigan Mark A et al.

The breast journal · 2018

PMID: 30014236

Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.

Partl Richard, Regitnig Peter, Tauber Gerlinde et al.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018

PMID: 28494403

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett John M S, Ahmed Ikhlaaq, Regan Meredith M et al.

European journal of cancer (Oxford, England : 1990) · 2017

PMID: 27269946

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens Charlotte, O'Leary Ben, Kilburn Lucy et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017